These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

225 related items for PubMed ID: 9180837

  • 1. [Negative second-look laparatomy in ovarian cancers. Survival analysis and prognostic factors from 64 cases treated at the Gustave Roussy Institute].
    Pautier P, Rey A, Michel G, Castaigne D, Rochard F, Duvillard P, Haie-Meder C, Curcio P, Benedetti-Richard L, Lhommé C.
    Bull Cancer; 1997 Feb; 84(2):147-54. PubMed ID: 9180837
    [Abstract] [Full Text] [Related]

  • 2. Long-term survival of 106 stage III ovarian cancer patients with minimal residual disease after second-look laparotomy and consolidation radiotherapy.
    Petit T, Velten M, d'Hombres A, Marchal C, Montbarbon X, Mornex F, Quetin P, Gérard JP, Romestaing P, Carrie C.
    Gynecol Oncol; 2007 Jan; 104(1):104-8. PubMed ID: 16987544
    [Abstract] [Full Text] [Related]

  • 3. Survival of women with advanced ovarian cancer and complete pathologic response at second-look laparotomy.
    Bolis G, Villa A, Guarnerio P, Ferraris C, Gavoni N, Giardina G, Melpignano M, Scarfone G, Zanaboni F, Parazzini F.
    Cancer; 1996 Jan 01; 77(1):128-31. PubMed ID: 8630918
    [Abstract] [Full Text] [Related]

  • 4. Long-term survival in advanced ovarian cancer after cytoreduction and chemotherapy treatment.
    Del Campo JM, Felip E, Rubio D, Vidal R, Bermejo B, Colomer R, Zanon V.
    Gynecol Oncol; 1994 Apr 01; 53(1):27-32. PubMed ID: 8175018
    [Abstract] [Full Text] [Related]

  • 5. Is there a role for second-look laparotomy in the management of malignant germ cell tumors of the ovary? Experience at Institut Gustave Roussy.
    Culine S, Lhomme C, Michel G, Leclere J, Duvillard P, Droz JP.
    J Surg Oncol; 1996 May 01; 62(1):40-5. PubMed ID: 8618400
    [Abstract] [Full Text] [Related]

  • 6. The recurrence and the overall survival rates of ovarian serous borderline neoplasms with noninvasive implants is time dependent.
    Silva EG, Gershenson DM, Malpica A, Deavers M.
    Am J Surg Pathol; 2006 Nov 01; 30(11):1367-71. PubMed ID: 17063075
    [Abstract] [Full Text] [Related]

  • 7. Analysis of treatment failures and survival of patients with fallopian tube carcinoma: a cooperation task force (CTF) study.
    Gadducci A, Landoni F, Sartori E, Maggino T, Zola P, Gabriele A, Rossi R, Cosio S, Fanucchi A, Tisi G.
    Gynecol Oncol; 2001 May 01; 81(2):150-9. PubMed ID: 11330942
    [Abstract] [Full Text] [Related]

  • 8. [Prognostic value of early normalization of CA 125 during chemotherapy in stages III and IV ovarian tumors].
    Ferrero JM, Largillier R, Ramaioli A, Heudier P, Teissier E, Namer M.
    Bull Cancer; 1997 Jul 01; 84(7):722-8. PubMed ID: 9339198
    [Abstract] [Full Text] [Related]

  • 9. Survival impact of surgical cytoreduction in stage IV epithelial ovarian cancer.
    Bristow RE, Montz FJ, Lagasse LD, Leuchter RS, Karlan BY.
    Gynecol Oncol; 1999 Mar 01; 72(3):278-87. PubMed ID: 10053096
    [Abstract] [Full Text] [Related]

  • 10. The benefits of comprehensive surgical staging in the management of early-stage epithelial ovarian carcinoma.
    Le T, Adolph A, Krepart GV, Lotocki R, Heywood MS.
    Gynecol Oncol; 2002 May 01; 85(2):351-5. PubMed ID: 11972399
    [Abstract] [Full Text] [Related]

  • 11. Surgical cytoreduction during second-look laparotomy in patients with advanced ovarian cancer.
    Gadducci A, Iacconi P, Fanucchi A, Cosio S, Teti G, Genazzani AR.
    Anticancer Res; 2000 May 01; 20(3B):1959-64. PubMed ID: 10928134
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Impact of second look laparotomy and secondary cytoreductive surgery at second-look laparotomy in ovarian cancer patients.
    Obermair A, Sevelda P.
    Acta Obstet Gynecol Scand; 2001 May 01; 80(5):432-6. PubMed ID: 11328220
    [Abstract] [Full Text] [Related]

  • 16. Tumor residual after surgical cytoreduction in prediction of clinical outcome in stage IV epithelial ovarian cancer: a Gynecologic Oncology Group Study.
    Winter WE, Maxwell GL, Tian C, Sundborg MJ, Rose GS, Rose PG, Rubin SC, Muggia F, McGuire WP, Gynecologic Oncology Group.
    J Clin Oncol; 2008 Jan 01; 26(1):83-9. PubMed ID: 18025437
    [Abstract] [Full Text] [Related]

  • 17. Second-look laparotomy in stage III epithelial ovarian cancer: clinical variables associated with disease status.
    Berek JS, Hacker NF, Lagasse LD, Poth T, Resnick B, Nieberg RK.
    Obstet Gynecol; 1984 Aug 01; 64(2):207-12. PubMed ID: 6539884
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Second-look laparotomy for ovarian cancer provides reliable prognostic information and improves survival.
    Friedman RL, Eisenkop SM, Wang HJ.
    Gynecol Oncol; 1997 Oct 01; 67(1):88-94. PubMed ID: 9345362
    [Abstract] [Full Text] [Related]

  • 20. Optimal cytoreductive surgery is an independent prognostic indicator in stage IV epithelial ovarian cancer with hepatic metastases.
    Naik R, Nordin A, Cross PA, Hemming D, de Barros Lopes A, Monaghan JM.
    Gynecol Oncol; 2000 Aug 01; 78(2):171-5. PubMed ID: 10926798
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.